ClinicalTrials.gg
RecruitingNCT07146100Updated Aug 18, 2026

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

An observational study in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. Recruiting at 37 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Ausper Biopharma Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. — 8 open to participants now, 11 under way, 1 of them phase 3. Hepatitis B, Chronic · Ausper Biopharma Co., Ltd..

Started
2025
with 4 others
Observational
Only one
of the 13
Primary completion
2028-01
later than 8 of 10 live
Registered
8th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., this one is one of 5 that started in 2025, is the only observational one, reaches primary completion later than 8 of the 10 other live ones, and was the 8th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

8 of the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., or all of them as a file.
02

Study summary

This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Hepatitis B, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants who have previously participated in AHB-137 clinical trials

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving .
  • Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.

Exclusion criteria

Exclusion Criteria:

  • Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.
  • Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants who have previously participated in AHB-137 clinical trials
06

What researchers measure

Primary outcomes

  1. Percentage of participants maintained complete response(defined as HBsAg < 0.05IU/mL and HBV DNA < lower limit of quantification).

    Time frame: Up to 80 weeks

Secondary outcomes

  1. Proportion of participants achieving and maintaining HBsAg<0.05 IU/mL.

    Time frame: Up to 80 weeks

  2. Time to loss of HBsAg reversion.

    Time frame: Up to 80 weeks

  3. Proportion and time of participants meeting certain test indicators after discontinuation of all CHB treatment.

    Time frame: Up to 80 weeks

  4. Serum levels of HBsAg, HBV DNA, HBV RNA, HBcrAg, HBsAb,HBeAb.

    Time frame: Up to 80 weeks

  5. Changes of the five-level five-dimensional health scale (EQ-5D-5L) instrument in participants compared with baseline.

    Time frame: Up to 80 weeks

  6. Percentage of participants with mutations

    Time frame: Up to 80 weeks

  7. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE), adverse events, hepatic endpoint events, deathsand clinically significant examination results.

    Examination including laboratory examination, electrocardiogram (ECG) examination.

    Time frame: Up to 80 weeks

  8. Changes of the hepatitis B quality of life (HBQOL) instrument in participants compared with baseline.

    Time frame: Up to 80 weeks

07

Study locations

8 of 37 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2028, 28 months after the start.

Of 72 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 28, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2030
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146100
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Aug 28, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Aug 18, 2026

Study contacts

Lu
Contact
clinicaltrial@ausperbio.com
0571-86959519
Jinlin Hou
principal investigator · Nanfang Hospital, Southern Medical University
Junqi Niu
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion